| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenues: | — | — | — | — | — | $0 |
| Research and development | $1.7M-3.5% | $1.8M+27.3% | $1.4M+22356.4% | $6K+25.4% | $5K-97.4% | $185K |
| General and administrative | $1.7M-8.9% | $1.9M-6.1% | $2.0M+210.5% | $652K+103.4% | $320K-63.3% | $874K |
| Total expenses | $3.4M-6.3% | $3.7M+7.4% | $3.4M+417.5% | $658K+102.2% | $325K-69.3% | $1.1M |
| Loss from operations | -$3.4M+6.3% | -$3.7M-7.4% | -$3.4M-417.5% | -$658K-102.2% | -$325K+69.3% | -$1.1M |
| Interest income | $126K-60.3% | $318K-16.0% | $379K | — | — | — |
| Net loss | -$3.3M+1.2% | -$3.3M-10.3% | -$3.0M-125.0% | $12.1M+4153.9% | -$299K+71.8% | -$1.1M |
| Basic net loss per share | -$0.02+0.0% | -$0.02+0.0% | -$0.02-166.7% | $0.03 | $0.00 | — |
| Diluted net loss per share | -$0.02+0.0% | -$0.02+0.0% | -$0.02-166.7% | $0.03 | $0.00 | — |
| Weighted average common stock shares outstanding - basic | 172.5M+0.1% | 172.3M+0.2% | 172.0M-53.0% | 366.2M-2.7% | 376.2M | — |
| Weighted average common stock shares outstanding - diluted | 172.5M+0.1% | 172.3M+0.2% | 172.0M-53.0% | 366.2M-2.7% | 376.2M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.